07:49 AM EDT, 10/16/2026 (MT Newswires) -- The European Medicines Agency's human medicines committee recommended Danish biopharmaceutical company Ascendis Pharma's Yuviwel drug for marketing authorization. The drug is intended to treat achondroplasia, a rare bone growth disorder, in children aged 2 and older whose epiphyses have not closed, according to a Friday release. The positive opinion is supported by a 52-week trial in which Yuviwel improved annualized growth velocity by 1.49 centimeters compared with placebo. The European Commission will make the final decision on marketing authorization.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.